NCT03138720 2026-04-22
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
HonorHealth Research Institute
Phase 2 Completed
Clinical Trials
11 trialsNCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
NCT04054362 2025-11-21
PINBALL
Barts & The London NHS Trust
Phase 2 Completed
NCT02030860 2025-07-25
A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03415854 2023-12-15
NABPLAGEMD
HonorHealth Research Institute
Phase 2 Completed
NCT02930902 2023-02-09
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03331562 2022-12-27
A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
Translational Genomics Research Institute
Phase 2 Completed
NCT03883919 2022-10-05
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Washington University School of Medicine
Phase 1 Completed
NCT00064376 2018-01-29
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
Cedars-Sinai Medical Center
Phase 2 Completed
NCT00637897 2017-05-30
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT00217477 2014-12-09
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
Roswell Park Cancer Institute
Phase 1 Completed